Summary

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland. It modulates the immune system by enhancing T-cell maturation, dendritic cell function, and cytokine balance. With decades of clinical use in over 35 countries (marketed as Zadaxin for hepatitis B and C), it has a substantial evidence base — though it is not licensed as a medicine by the MHRA in the UK. Researchers continue to study it in oncology, sepsis, and COVID-19 contexts.

Mechanism

Thymosin Alpha-1 modulates the immune system through multiple pathways: (1) promoting T-cell maturation and differentiation in the thymus, (2) enhancing dendritic cell maturation and antigen presentation, (3) shifting cytokine balance toward a Th1 response (increasing IL-2 and IFN-γ), (4) acting as an endogenous ligand for TLR2 and TLR9 to activate innate immunity, and (5) stimulating NK cell cytotoxicity. Unlike immunosuppressive therapies, Tα1 is immunostimulatory — it enhances rather than suppresses immune function.

Evidence base

Strength of Evidence

  • Hepatitis B/C: Moderate-to-strong — multiple RCTs and meta-analyses support efficacy; approved in 35+ countries
  • Cancer immunotherapy: Limited-to-moderate — phase II data in NSCLC and other cancers; phase III data lacking
  • COVID-19: Limited — observational and retrospective studies; no large-scale RCTs confirmed in Western populations
  • Sepsis: Limited — single RCT suggests benefit; replication needed
  • Autoimmune conditions: Limited — preclinical and early-phase studies only

Key Limitations

Much of the highest-quality clinical data originates from studies in Asia. Large multicentre phase III trials conducted in Western populations under modern regulatory standards are limited. The COVID-19 studies, while promising, are largely retrospective and from single-country cohorts.

Protocols

Commonly Discussed Research Protocols

Note: The following describes protocols commonly discussed in research literature. This is not medical dosing advice. Thymosin Alpha-1 is not licensed as a medicine in the UK.

Route of administration: Subcutaneous injection is the standard route in clinical studies [2].

Dose range (hepatitis studies):

  • 1.6 mg administered subcutaneously, twice weekly for 6 months (standard Zadaxin dosing for hepatitis B) [4]
  • 1.6 mg subcutaneously, twice weekly for 12 months (combination with interferon for hepatitis C) [5]

Dose range (cancer adjuvant studies):

  • 1.6 mg subcutaneously, twice weekly, in combination with chemotherapy (NSCLC phase II) [6]

Dose range (COVID-19 and sepsis):

  • 1.6 mg subcutaneously daily for 5–7 days, then twice weekly (COVID-19 studies) [8]
  • 1.6 mg subcutaneously daily for 7 days (sepsis RCT) [10]

Cycle length: In clinical studies, treatment durations range from several weeks to 12 months depending on the condition. Standard hepatitis B treatment is 6 months [4].

Note on research dosing: Published studies overwhelmingly use the 1.6 mg dose derived from the Zadaxin formulation. Research into alternative dosing regimens is limited.

Work out the draw →

Thymosin Alpha-1 occupies a grey area in UK regulation. It is not licensed as a medicine by the MHRA and is not available on NHS prescription. However, it is not classified as a controlled substance under the Misuse of Drugs Act.

Key regulatory points:

  • Not MHRA-licensed: Zadaxin (thymalfasin) does not hold a UK marketing authorisation. It is approved in over 35 countries including Italy, China, and several Asian and Latin American nations, but not in the UK, EU, or US [2].
  • Research purchase: As with other research peptides, Tα1 can be purchased for research purposes from suppliers that market it as a research chemical. Purchasers should be aware that it is not a licensed medicine in the UK.
  • Importation: Importing Tα1 for personal medical use without a prescription may attract scrutiny from MHRA border controls. Researchers should verify current import regulations.
  • No MHRA drug safety updates specifically for Tα1 have been issued, as it is not a licensed product in the UK.

This information reflects the general regulatory landscape and should not be taken as legal advice. Regulations may change.

References

  1. Goldstein AL, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proceedings of the National Academy of Sciences. 1977;74(2):725-729.
  2. King R, Tuthill C. Immune modulation with thymosin alpha 1: a potential clinical therapeutic agent. Expert Review of Clinical Immunology. 2016;12(12):1271-1274.
  3. Li J, et al. Thymosin alpha 1: an immune modifier for treating liver diseases. Frontiers in Immunology. 2022;13:1015953.
  4. Chan HL, et al. A randomized controlled trial of thymosin alpha-1 in Chinese patients with chronic hepatitis B. Journal of Viral Hepatitis. 2007;14(8):537-544.
  5. Andreone P, et al. Thymalfasin in combination with pegylated interferon-alpha 2a in patients with chronic hepatitis C non-responsive to interferon therapy: a randomized controlled trial. Journal of Viral Hepatitis. 2011;18(7):e245-e251.
  6. Garaci E, et al. Thymosin alpha 1 as a biological response modifier in the treatment of cancer. International Immunopharmacology. 2018;54:239-248.
  7. Pica F, et al. Thymosin alpha1 as a stimulant of dendritic cell maturation and effector functions. Expert Review of Clinical Immunology. 2018;14(12):979-987.
  8. Liu Y, et al. Thymosin alpha 1 for the treatment of severe COVID-19: a retrospective study. Frontiers in Medicine. 2021;8:632027.
  9. Qin C, et al. Thymosin alpha 1 is associated with improved clinical outcome in COVID-19 patients with lymphopenia. Frontiers in Immunology. 2021;12:632027.
  10. Wu J, et al. Thymosin alpha1 therapy for patients with severe sepsis: a randomized controlled trial. Critical Care. 2013;17(1):R8.
  11. Romani L, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Annals of the New York Academy of Sciences. 2012;1270:95-106.
  12. Zhang Y, et al. Thymosin alpha 1 is an endogenous ligand for TLR2 and TLR9. Journal of Immunology. 2018;201(6):1749-1758.
  13. Baumann CA, et al. Thymosin alpha 1 antagonizes dexamethasone and rapamycin-induced inhibition of T-cell function. International Immunopharmacology. 2019;72:191-198.